Unveiling Violations
Investors in Allarity Therapeutics, Inc. get ready! The Law Offices of Howard G. Smith issued a poignant reminder about the impending deadline to act as lead plaintiff in the lawsuit against the company. This legal battle stems from a case representing those who bought Allarity securities between May 17, 2022, and July 19, 2024. The alarm is set for November 12, 2024, marking the final call for any affected investor to step up.
Stock Under Siege
Allarity Therapeutics, Inc. hit rough waters recently. In February 2023, the company felt the first tremor when it disclosed an SEC investigation related to federal securities laws violations. This revelation wasn’t just some storm in a teacup; it caused a 3.8% drop in Allarity’s share price. Fast forward to December 2023, the storm clouds gathered darker, with the company’s CEO ousted from his position, resulting in a daunting 13.4% stock price plummet. Then, a final blow on July 22, 2024, as news of a Wells Notice from the SEC sent the stock price tumbling by 2.4%. Investors were grasping at straws on a sinking ship.
Allegations Unearthed
The lawsuit filed reveals a tapestry of deceit painted by the defendants during the Class Period. Allarity Therapeutics, Inc. and its former officers allegedly engaged in fraudulent activities surrounding the Dovitinib NDA and the Dovitinib-DRP PMA. This deception left the company susceptible to regulatory scrutiny and potential legal repercussions, causing harm to its reputation and investors’ pockets. The lack of transparency from the defendants translated into a financial nightmare for investors, who were misled about the company’s true state of affairs.
Call to Action
For investors caught in the whirlwind, the time to act is now. By November 12, 2024, interested parties must make their move to potentially serve as the lead plaintiff in this legal drama. Failure to engage in this critical period could result in missing out on a chance to seek justice. Those affected are urged to contact the Law Offices of Howard G. Smith promptly to discuss their position and explore their rights in this case. The clock is ticking, and investors must decide whether to navigate the legal waters or risk remaining a bystander in this tumultuous journey.
Remember, in the thicket of legal proceedings, being informed and proactive is akin to having a life jacket on a turbulent sea. So, investors, heed the cautionary tale of Allarity Therapeutics, Inc., and take charge of your investment destiny before the final gavel falls.
Disclaimer Disclosure
This informative piece may constitute Attorney Advertising in certain jurisdictions as per relevant laws and ethical standards.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240920943282/en/
Market News and Data brought to you by Benzinga APIs